Rice Hall James & Associates LLC increased its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report) by 3.2% in the 4th quarter, Holdings Channel reports. The institutional investor owned 596,431 shares of the company’s stock after purchasing an additional 18,609 shares during the period. Kiniksa Pharmaceuticals International accounts for 1.4% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 22nd largest holding. Rice Hall James & Associates LLC’s holdings in Kiniksa Pharmaceuticals International were worth $24,603,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently bought and sold shares of the business. Mark Sheptoff Financial Planning LLC boosted its holdings in Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock worth $674,000 after buying an additional 250 shares during the period. Mariner LLC boosted its holdings in Kiniksa Pharmaceuticals International by 2.0% in the 4th quarter. Mariner LLC now owns 13,519 shares of the company’s stock worth $558,000 after buying an additional 266 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares during the period. CWM LLC boosted its holdings in Kiniksa Pharmaceuticals International by 3.9% in the 4th quarter. CWM LLC now owns 20,605 shares of the company’s stock worth $850,000 after buying an additional 764 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Kiniksa Pharmaceuticals International by 4.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company’s stock worth $701,000 after buying an additional 771 shares during the period. 53.95% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 58,424 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $53.71, for a total value of $3,137,953.04. Following the transaction, the insider directly owned 65,623 shares in the company, valued at $3,524,611.33. This represents a 47.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the company’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total value of $656,259.90. Following the completion of the transaction, the director owned 12,546 shares in the company, valued at $628,554.60. This represents a 51.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International Stock Up 0.9%
Shares of NASDAQ KNSA opened at $52.34 on Tuesday. The firm has a market capitalization of $4.03 billion, a P/E ratio of 58.16 and a beta of 0.12. The stock’s 50-day simple moving average is $50.57 and its two-hundred day simple moving average is $46.03. Kiniksa Pharmaceuticals International, plc has a twelve month low of $26.27 and a twelve month high of $59.87.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last announced its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. The business had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.11 EPS. As a group, research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current fiscal year.
Kiniksa Pharmaceuticals International Profile
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.
Read More
- Five stocks we like better than Kiniksa Pharmaceuticals International
- Father’s Day Investing: 3 Stocks Built for Long-Term Returns
- This Golden Cross Could Send Urban Outfitters to New Highs
- Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold?
- Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?
Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report).
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
